Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach

Cancers

Joong Hyun Ahn¹  Seunghak Lee²  Se-Hoon Lee³  Chorog Song⁴  Ho Yun Lee⁴  Hyunjin Park⁵ 

[1] Biostatistics and Clinical Epidemiology Center, Samsung Biomedical Research Institute, Seoul 135710, Korea;Core Research & Development Center, Korea University Ansan Hospital, Ansan 15355, Korea;Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06355, Korea;Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea;School of Electronic and Electrical Engineering, Sungkyunkwan University, Suwon 16419, Korea;

关键词: NSCLC;    ICI;    radiomics;   

DOI  :  10.3390/cancers13236050

来源: DOAJ

【 摘 要 】

Conventional methods to determine the response to immune checkpoint inhibitors (ICIs) are limited by the unique responses to an ICI. We performed a radiomics approach for all measurable lesions to identify radiomic variables that could distinguish hyperprogressive disease (HPD) on baseline CT scans and classify a dissociated response (DR). One hundred and ninety-six patients with advanced lung cancer, treated with ICI monotherapy, who underwent at least three CT scans, were retrospectively enrolled. For all 621 measurable lesions, HPDv was determined from baseline CT scans using the tumor growth kinetics (TGK) ratio, and radiomics features were extracted. Multivariable logistic regression analysis of radiomics features was performed to discriminate DR. Radiomics features that significantly discriminated HPDv on baseline CT differed according to organ. Of the 196 patients, 54 (27.6%) had a DR and 142 (72.4%) did not have a DR. Overall survival in the group with a DR was significantly inferior to that in the group without a DR (log rank test, p = 0.04). Our study shows that lesion-level analysis using radiomics features has great potential for discriminating HPDv and understanding heterogeneous tumor progression, including a DR, after ICI treatment.

【 授权许可】

Unknown